Why is glioblastoma so deadly? DelMar discusses the need for new cancer research and treatments for Brain Tumor Awareness Month
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (ÒDelMar PharmaÓ or ÒDelMarÓ) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.